Yamaguchi K, Aoyagi K, Urakami K, Fukutani T, Maki N, Yamamoto S, Otsubo K, Miyake Y, Kodama T
Growth Factor Division, National Cancer Center Research Institute, Tokyo.
Jpn J Cancer Res. 1995 Jul;86(7):698-705. doi: 10.1111/j.1349-7006.1995.tb02455.x.
Our previous study demonstrated that pro-gastrin-releasing peptide(31-98), or ProGRP, is a specific tumor marker in patients with small cell lung carcinoma (SCLC). Using a newly developed, highly sensitive enzyme-linked immunosorbent assay (ELISA) for ProGRP, we analyzed 1,446 samples including those obtained from 478 lung cancer patients to evaluate the clinical usefulness of this ELISA. Several properties indicated that ProGRP is a useful tumor marker for SCLC. First, ProGRP was specifically elevated in SCLC patients. In non-SCLC patients and patients with non-tumorous lung diseases, its serum level was very rarely elevated. Secondly, ProGRP was a reliable marker, in terms of the marked elevation of serum ProGRP levels in SCLC patients. Thirdly, serum ProGRP levels were elevated in SCLC patients even at a relatively early stage of this disease. Fourthly, changes in the serum ProGRP level showed an excellent correlation with the therapeutic responses in SCLC patients. Neuron-specific enolase (NSE) is accepted as a tumor marker of SCLC patients. With the aim of comparing ProGRP and NSE as tumor markers for SCLC patients, we measured serum NSE levels in all samples collected in the present study. We found that ProGRP was superior to NSE in terms of sensitivity, specificity and reliability. Therefore, we consider that ProGRP can play a major role as a clinical tumor marker for SCLC patients.
我们之前的研究表明，胃泌素释放肽原（31 - 98），即ProGRP，是小细胞肺癌（SCLC）患者的一种特异性肿瘤标志物。我们使用新开发的、高度灵敏的ProGRP酶联免疫吸附测定（ELISA）方法，分析了1446份样本，包括从478例肺癌患者获得的样本，以评估该ELISA的临床实用性。多项特性表明ProGRP是SCLC的一种有用的肿瘤标志物。首先，ProGRP在SCLC患者中特异性升高。在非SCLC患者和非肿瘤性肺部疾病患者中，其血清水平极少升高。其次，就SCLC患者血清ProGRP水平显著升高而言，ProGRP是一个可靠的标志物。第三，即使在SCLC疾病的相对早期阶段，患者血清ProGRP水平也会升高。第四，血清ProGRP水平的变化与SCLC患者的治疗反应显示出极好的相关性。神经元特异性烯醇化酶（NSE）被公认为SCLC患者的肿瘤标志物。为了比较ProGRP和NSE作为SCLC患者肿瘤标志物的情况，我们测量了本研究中收集的所有样本的血清NSE水平。我们发现，在敏感性、特异性和可靠性方面，ProGRP优于NSE。因此，我们认为ProGRP可作为SCLC患者的临床肿瘤标志物发挥主要作用。
